SUNNYVALE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...
Protocol Expansion Broadens Phase 3 HERO Trial Eligibility Criteria to Include Children Ages 7+ in the United StatesSAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) ...
SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate ...
The FDA approved protocol updates to a tasquinimod trial in myelofibrosis, allowing broader enrollment and combination use ...
MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based ...
Please provide your email address to receive an email when new articles are posted on . The SOL trial will now include treatment-naïve patients with wet AMD and visual acuity of 20/80 or better at ...
Anixa Biosciences, Inc. ANIX on Monday provided an update on patient outcomes observed in its ongoing Phase 1 ovarian cancer ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced ...
Patented personalized medicine approach for patient dosing for autologous cell therapy Expected to meaningfully enhance clinical experience and market opportunity SUNNYVALE, Calif., Aug. 21, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results